Sutro Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by Sutro Biopharma, Inc. on June 5, 2020. The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol STRO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
The primary material event reported is the outcome of the stockholder vote at the Annual Meeting. No financial material changes versus prior periods are disclosed in this document.
Corporate Actions and Governance
- Director Elections: Stockholders elected three Class II directors to serve three-year terms expiring at the 2023 Annual Meeting:
- William J. Newell: 15,003,659 shares For; 826,091 shares Withheld.
- Connie Matsui: 14,970,091 shares For; 859,659 shares Withheld.
- James Panek: 15,811,205 shares For; 18,545 shares Withheld.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Votes For: 16,671,211
- Votes Against: 5,230
- Votes Abstaining: 0
Key Facts for Investor Verification
- Verify the full slate of directors elected and their specific terms of service.
- Confirm the appointment of Ernst & Young LLP for the 2020 fiscal year audit.
- Note that this filing contains no financial results; refer to the most recent 10-K or 10-Q for financial metrics.
- Review the proxy statement for detailed biographies of the newly elected directors.